Loading…
Rapport Therapeutics, Inc. is projected to rise to $56.54 by 2027, a +32% move from its current price of $42.78. RAPP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $41.59 | $42.79 | $44.01 | +0.01% |
| Aug 2 | $41.12 | $42.79 | $44.53 | +0.02% |
| Aug 3 | $40.75 | $42.80 | $44.94 | +0.04% |
| Aug 4 | $40.45 | $42.80 | $45.29 | +0.05% |
| Aug 5 | $40.19 | $42.81 | $45.60 | +0.06% |
| Aug 6 | $39.95 | $42.81 | $45.88 | +0.07% |
| Aug 7 | $39.73 | $42.82 | $46.14 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $39.73 | $42.82 | $46.14 | +0.09% |
| Week 2 | $38.56 | $42.85 | $47.63 | +0.17% |
| Week 3 | $37.69 | $42.89 | $48.82 | +0.26% |
| Week 4 | $36.97 | $42.93 | $49.85 | +0.35% |
| Week 5 | $36.36 | $42.97 | $50.78 | +0.44% |
| Week 6 | $35.81 | $43.00 | $51.64 | +0.52% |
| Week 7 | $35.32 | $43.04 | $52.45 | +0.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing transformational small molecule medicines for central nervous system (CNS) disorders.
Its lead candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders.
The company also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts, and it was formerly known as Precision Neuroscience NewCo, Inc.
and changed its name to Rapport Therapeutics, Inc. in October 2022.
Rapport Therapeutics, Inc. trades under the symbol RAPP. It is currently priced at $42.78 per share, with a market capitalization of $2.05B and a rank of 1892 by market size.
The stock sits in a bullish technical context, with RSI(14) at 60 and a 50-day simple moving average of $39.14 versus a 200-day SMA of $32.03, indicating positive near-term momentum.
Key support and resistance are listed at $36.87 and $42.78, and the 30-day price range spans $35.51 to $51.53. Annualized volatility is quoted at 50%.
Overall, current fundamentals paired with the technical read suggest a constructive near-term posture within the broader bullish outlook.
A major floor 35.3% below — a decisive break under it would weaken the trend.
The nearest floor, 13.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 9.2% above — clearing it would confirm fresh momentum.
Key RAPP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RAPP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $41.70 | Buy | $41.86 | Buy |
| MA 10 | $41.66 | Buy | $41.58 | Buy |
| MA 20 | $41.09 | Buy | $41.02 | Buy |
| MA 50 | $39.14 | Buy | $39.31 | Buy |
| MA 100 | $36.24 | Buy | $36.67 | Buy |
| MA 200 | $32.03 | Buy | $32.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.39 | Neutral |
| Stoch RSI (14) | 63.19 | Neutral |
| CCI (20) | 112.34 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 3.18 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | 1.59 | Buy |
| Ultimate (7,14,28) | 53.08 | Neutral |
| Momentum (10) | 2.65 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 41.93 | Buy |
| ADX (14) | 11.44 | Neutral |
| ATR (14) | 1.13 | Info |
The 30-day picture is bullish, with RSI(14) at 60 and the 50-day SMA of $39.14 above the 200-day SMA of $32.03, signaling positive near-term momentum.
Support sits at $36.87 and resistance at $42.78, with the 30-day trading range from $35.51 to $51.53. The setup implies potential upside within the near term while volatility remains a consideration given the 50% annualized figure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.55 | $42.78 | $55.29 | 0% | Neutral | |
| $44.95 | $56.54 | $75.28 | +32% | Bullish | |
| $47.92 | $62.08 | $85.92 | +45% | Bullish | |
| $51.95 | $68.94 | $98.33 | +61% | Bullish | |
| $67.96 | $92.14 | $134.77 | +115% | Bullish | |
| $82.36 | $113.85 | $170.21 | +166% | Bullish | |
| $97.15 | $136.74 | $208.50 | +220% | Bullish | |
| $107.90 | $154.48 | $239.77 | +261% | Bullish | |
| $107.40 | $156.27 | $246.54 | +265% | Bullish | |
| $122.42 | $180.91 | $289.77 | +323% | Bullish | |
| $204.81 | $324.65 | $554.04 | +659% | Bullish | |
| $372.68 | $666.90 | $1,247.95 | +14.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $25.55 | $42.78 | $49.87 | +0.00% |
| August 2026 | $35.95 | $42.23 | $50.77 | -1.29% |
| September 2026 | $36.52 | $43.27 | $52.75 | +2.47% |
| October 2026 | $36.51 | $43.55 | $53.68 | +0.66% |
| November 2026 | $35.76 | $42.90 | $53.34 | -1.51% |
| December 2026 | $36.58 | $44.11 | $55.29 | +2.83% |
Click any year to see its month-by-month RAPP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RAPP could reach as high as $55.29, with a base case around $42.78 and support toward $25.55 — roughly 0% from $42.78. Price action looks broadly range-bound.
Expect RAPP to range from $44.95 to $75.28 through 2027. The $56.54 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The RAPP price prediction for 2028 points to an average of $62.08 (low $47.92, high $85.92) — a potential gain of +45% on today's $42.78. Momentum favours further upside here.
In 2029, RAPP is projected to trade between $51.95 and $98.33, averaging $68.94 — a potential gain of +61% from today's $42.78. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Rapport Therapeutics, Inc.'s 2030 outlook centres on $92.14, within a $67.96 to $134.77 range. That is up +34% on the projected 2029 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2031, RAPP could reach as high as $170.21, with a base case around $113.85 and support toward $82.36 — roughly +166% from $42.78. Buyers look set to stay in control over this stretch.
Expect RAPP to range from $97.15 to $208.50 through 2032. The $136.74 average target implies a +220% move from current prices. That is up +20% on the projected 2031 average. Momentum favours further upside here.
The RAPP price prediction for 2033 points to an average of $154.48 (low $107.90, high $239.77) — a potential gain of +261% on today's $42.78. Buyers look set to stay in control over this stretch.
In 2034, RAPP is projected to trade between $107.40 and $246.54, averaging $156.27 — a potential gain of +265% from today's $42.78. That is up +1% on the projected 2033 average. Momentum favours further upside here.
Rapport Therapeutics, Inc.'s 2035 outlook centres on $180.91, within a $122.42 to $289.77 range. That is up +16% on the projected 2034 average. That marks a +323% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RAPP could reach as high as $554.04, with a base case around $324.65 and support toward $204.81 — roughly +659% from $42.78. Momentum favours further upside here.
Expect RAPP to range from $372.68 to $1,247.95 through 2050. The $666.90 average target implies a +14.6x move from current prices. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RAPP today (≈ 23.375409 RAPP) could be worth
$15,589.02
+$14,589.02 (+1459%) by 2050 · US Dollar
Based on the average projected RAPP price of $666.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAPPwould be worth at today's price.
$1,000 invested in RAPP on Jul 30, 2025 (≈ 67.430884 RAPP) would be worth
$2,884.69
+$1,884.69 (+188.5%) today · 2.88× · US Dollar
Based on a RAPP entry price of $14.83 vs. today's $42.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $41.38 | $1,033.83 | +3.4% |
| 1 month ago | $41.67 | $1,026.64 | +2.7% |
| 3 months ago | $33.89 | $1,262.32 | +26.2% |
| 6 months ago | $26.61 | $1,607.67 | +60.8% |
| 1 year ago | $14.83 | $2,884.69 | +188.5% |
| All time (2.1y) ago | $20.8 | $2,056.73 | +105.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RAPP forecast.
Our base-case forecast reaches $86.00 around 2030.
Implied market cap at $86.00: $4.11B
The year-by-year forecast outlines a clear bullish trajectory across major years. The 2026 average price is $42.78, the 2027 average is $56.54, and the 2028 average is $62.08, with corresponding min/max points of $25.55/$55.29, $44.95/$75.28, and $47.92/$85.92 respectively.
By 2030, the forecasted average price is $92.14, with a min of $67.96 and a max of $134.77, delivering an ROI of 115.4% and a bullish sentiment. Beyond 2030, the path remains bullish, with the 2040 average of $324.65 (ROI 658.9%) and the 2050 average of $666.90 (ROI 1458.9%), signaling substantial long-term upside.
Across the horizon, sentiment is Bullish from 2027 onward, with a neutral stance in 2026. These figures are estimates and illustrate a potential growth path, not a guaranteed outcome, and actual results may differ.
Tap a question to reveal the answer.
The forecast shows a 2030 average price of $92.14, with a min of $67.96 and a max of $134.77, and a 115.4% ROI; the sentiment is BULLISH.
The outlook is bullish from 2027 onward, with rising averages (2027 avg $56.54, 2028 avg $62.08, 2029 avg $68.94, 2030 avg $92.14) and ROIs of 32.2%, 45.1%, 61.1%, and 115.4% respectively; 2026 is neutral.
Yes—the 2030 max forecast is $134.77, which is above $100.
Current price is $42.78 and market capitalization is $2.05B.
The forecast shows a bullish path with rising averages and ROIs (e.g., 2030 avg $92.14 and ROI 115.4%, 2040 avg $324.65 and ROI 658.9%, 2050 avg $666.90 and ROI 1458.9%), but these are estimates and not guarantees; explicit drivers and risks are not detailed in the provided figures.
Rapport Therapeutics, Inc. Community Discussion
0Share your Rapport Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.